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A  tacit  assumption  of  cancer  immunology  has  been 
that tumors express non-self or "foreign" antigens. The 
recent identification of a handful of potentially immunogenic 
cancer antigens shows that they are not truly foreign. Although 
the boundary between self and non-self is not well-defined, 
this first look at cancer antigens fits more with a self/altered 
self paradigm than with the non-self paradigm for antigens 
recognized in infectious diseases. 
Tumor-specific Antigens in Animal Models 
The experimental foundation for cancer immunology comes 
largely from studies of immune rejection of chemically- and 
UV radiation-induced  tumors in syngeneic mice.  The  an- 
tigens  defined in  these mouse systems are potent,  tumor- 
specific determinants, recognized by CTLs that are expressed 
by tumor cells but not by normal ceUs or even by indepen- 
dently derived tumors (1, 2). Studies by Boon and co-workers 
have provided a model for the origin of tumor-specific an- 
tigens, using the mouse P815 mastocytoma tumor (3-6). Treat- 
ment of P815 cancer cells in vitro with a mutagen was used 
to generate variant cancer cells,  called turn-,  that  failed to 
produce tumors because of stimulation  of strong CTL re- 
sponses.  The mutagen generated single nucleotide mutations 
in coding regions, altering solitary amino acids and creating 
new antigens for a CTL response to altered self. These single 
amino acid mutations provided either a new epitope for TCR 
recognition or a new agretope for binding to MHC mole- 
cules (3, 4). In either case, epitope or agretope, the antigen 
was tumor specific because it was presented through MHC 
only by the mutagenized malignant clone. The determinants 
were unique to the tumor,  even though the original,  non- 
mutated gene could be ubiquitously expressed, providing a 
structural  basis for tumor-specific recognition  (3). 
A striking finding was that immunization  with mutage- 
nized  turn-  cells  could induce  protection  against  the  pa- 
rental tumor ceUs, even if the original  tumor was a poorly 
immunogenic, spontaneous tumor (5, 6). These experiments 
provide a strong indication that even apparently weakly im- 
munogenic cancers can be rejected by an immune response 
after effective immunization.  Thus, all tumors may have an- 
tigens that  can be recognized by the immune  system, but 
the immunogenicity of these antigens can vary from potent 
antigens in chemically induced tumors to low inherent im- 
munogenicity in  spontaneous  tumors. 
Recognition of point mutation is not the only model for 
tumor rejection in the P815 model. Two CTL clones against 
P815 variants reacted with the product of a gene, called P1A, 
that was completely identical to the gene present in normal 
tissues of the mouse (7). The antigen encoded by PIA was 
expressed not only by P815, but also by an unrelated mast 
cell line derived from the syngeneic mouse strain.  This finding 
raised the prospect that shared, nonmutated antigens can be 
recognized by T cells on tumors of the same histologic type. 
Recognition  of Differentiation Antigens on Human  Cancers 
A body of data over the past two decades has determined 
that the immune repertoire of persons with cancer contains 
B and T  cells that  recognize antigens expressed by autolo- 
gnus cancer cells. Thus, tolerance to human cancer, if it exists, 
does not delete the immune repertoire against the cancer cell. 
The known universe of immunogenic antigens (i.e., defined 
by structure or sequence) on human cancers is small, but is 
expanding rapidly (Table 1). In contrast to the classical mouse 
studies, the human immune system appears to recognize an- 
tigens expressed by normal tissues.  The immune repertoire 
to melanoma is the most extensively characterized of any cancer 
in humans. The serological analysis of human melanoma has 
shown  that  antigens  expressed  on  cancer  cells reflect  the 
differentiation state of the normal cell counterpart (melano- 
cyte) at the same stage of differentiation (8). Immune recog- 
nition of melanocyte differentiation antigens has been demon- 
strated for high affinity IgG autoantibodies against melanoma 
(9). This paradigm of differentiation antigens is now being 
revisited based on recent knowledge of T  cell recognition 
of human melanoma. This is exemplified by a report in this 
issue by Coulie et al.  (10) and two reports by Kawakami et 
al.  (11, 12) describing an antigen,  called Melan-A or mela- 
noma antigen recognized by T cells 1 (MART-I), expressed 
by melanoma, melanocytes, and pigmented retinal cells but 
not other normal tissues.  This melanocyte differentiation an- 
tigen was presented to CTL of at least 11 different persons 
through class I MHC HLA-A2.1 molecules expressed by mela- 
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Volume 180  July 1994  1-4 Table  1.  Antigens  on Autologous  Human  Cancers Recognized  by Antibody  or T  Cell Responses 
Tumor  Normal  tissue 
Antigen  type  expression  Comments  Rf 
Antibody  gp75/brown  Melanoma  Melanocytes  Melanosomal protein  13 
Gangliosides  Melanoma  Neuroectoderm-  Carbohydrate  antigens  20 
(GM2,  GD2)  derived tissues 
Melanotransferrin  Melanocytes, 
other tissues 
HER2/neu  Epithelium 
T  cell 
p53,  nonmutant 
T,Tn,sialylTn 
MAGE-1,3 
T yrosinase /albino 
MUC1 
Melan-A/MART-1 
Melanoma 
Breast 
Breast 
Breast 
Melanoma,  lung,  and 
other cancers 
Melanoma 
Pancreas, 
breast 
Melanoma 
Most cells 
Epithelium 
Testes 
Melanocytes 
Epithelium 
Melanocytes 
pMe117/silver?  Melanoma  Melanocytes 
Potential  unique 
determinant 
Overexpressed  on a 
proportion of cancers 
No recognition  of 
mutant  p53 
Carbohydrate  antigens 
Not expressed by 
melanocytes 
Melanosomal protein 
Non-MHC restricted 
Melanocytes and retina 
Melanosomal protein 
21 
22 
23 
20 
17 
18 
12 
24 
9 
10 
11 
14 
15 
Antigens with known structures that are recognized on autologous tumor cells. 
R  f, reference number. 
noma (10-12). This defines a true shared tumor antigen, ex- 
pressed by tumors in different hosts and recognized by more 
than  one patient. 
The Melan-A antigen  is now the fourth autoantigen  on 
human melanoma that is specifically expressed by normal mel- 
anocytes. CTL clones of one of the patients who responded 
to Melan-A also recognized another normal melanocyte con- 
stituent,  tyrosinase, presented by HLA-A2.1 (10,  13). This 
patient did not have overt signs of autoimmunity (e.g., depig- 
mentation) and yet had an extraordinarily good clinical course 
after multiple resections of metastatic melanoma.  Although 
one cannot generalize too much from a single patient, clues 
often arise  from these case studies.  In this case,  the clue is 
that immune responses to restricted melanocyte differentia- 
tion  antigens  might  prevent progression  of the cancer. 
The identity and cellular localization of Melan-A remains 
unknown. However, three other autoantigens on melanoma 
are transmembrane glycoproteins expressed within melano- 
somes, the melanocyte-specific organelle that  is the site of 
melanin  synthesis. These are tyrosinase (the product of the 
c or albino locus), gp75 (the product of the brown locus), and 
gpl00 (mapping near or within the silver locus) (9,  13-15). 
A peptide within gpl00 defines another shared epitope, rec- 
ognized by CTL from nine melanoma patients  (14-16).  It 
is worth pointing out that each of these products is the human 
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homologue of a gene or genetic region that determines coat 
color in the mouse. Why melanosomal glycoproteins are so 
readily recognized by the immune system remains a mystery. 
Another  model  for recognition  of self molecules is ex- 
emplified by the MAGE-1 and MAGE-3 antigens systems (17, 
18). MAGE-1 and -3 are expressed on melanoma (and other 
tumor types), but not on normal melanocytes or most other 
normal  tissues.  In  normal  tissues,  MAGE-1  and  -3 appear 
to be restricted to the testes (17, 18). Although the exact cell 
type in the testes is not yet identified, the MAGE genes could 
be regulated  during  spermatogenesis or early development 
and then remain  silent (except after malignant  transforma- 
tion). Discovering the functions of these genes will provide 
further  insights. 
There  are several points  to make about this  universe of 
human cancer antigens  (Table  1).  First,  these studies are at 
an early stage, and the majority of work in human cancer 
to date has been done in melanoma.  It would be premature 
to generalize to all cancers at this point. Second, the majority 
of antigens recognized by the immune  system is expressed 
both by the malignant cell and normal cell counterpart (e.g., 
melanoma and melanocyte), and therefore represents an ap- 
parent autoimmune recognition. Third, the evidence to date 
reflects immune repertoire, i.e., it is not yet possible to know 
whether T cell or antibody responses truly represent immune rejection of cancer. Distinguishing immune repertoire from 
a protective immune response in vivo and in situ will be crit- 
ical. Evidence for high titer, high affinity IgG antibody re- 
sponses or high precursor frequencies of T cells is consistent 
with a specific immune response  to the tumor in vivo, but 
it is possible that these responses  are not to the tumor but 
to tissue injury or some other event in the host. 
If self proteins of human cancer can be recognized by CTLs, 
can T cells recognize mutations, for instance ras, p53, or other 
altered alleles? Mutations in ras and p53 are not common in 
human melanoma, and it is too early to know the frequency 
of immune recognition of these mutations in other cancers. 
These are certainly attractive targets. However, whether these 
are realistic  epitopes for the immune response  is uncertain. 
Evidence points to the likelihood that there are T  cells in 
the immune repertoire that can recognize mutant ras pep- 
tides (19). Yet it is possible  that many mutations are not 
presented to the immune system on MHC molecules of human 
cancer cells. Presentation would require appropriate processing 
and trimming of peptides, transport to the correct compart- 
ment for MHC binding, and expression  of an appropriate 
MHC allele that could accept  the peptide.  If strongly im- 
munogenic mutations were presented by the tumor, clones 
could be destroyed by an immune response,  but surviving 
tumor clones could avoid the response by mutation or down- 
regulation of the gene encoding the peptide, or by down- 
regulation of  MHC, peptide transporter, or other escape routes. 
In particular, if the mutation is not crucial  to maintaining 
the malignant or metastatic phenotype, then subclones  not 
expressing the mutant peptide might readily survive. 
Mutations appear  to accumulate progressively in human 
cancers, particularly during later stages of tumor progression. 
In contrast, chemically induced tumors acquire a large number 
of mutations simultaneously at an early stage of tumor de- 
velopment. The expression of potent unique tumor rejection 
antigens in chemically induced tumors may reflect the acqui- 
sition of a large number of mutations early in tumor progres- 
sion, allowing less chance for selection by the immune system, 
and providing a stochastic model for recognition of these 
unique antigens. 
Final Comments 
Human studies of immune responses to cancer have shown 
that normal differentiation antigens are recognized by the 
host. In this respect, tumor immunology shares common fea- 
tures with the study of autoimmune disease. Both fields are 
concerned with the immune response to cellular antigens and 
the role of this response in the pathogenesis of disease. How- 
ever, the therapeutic goals of tumor immunology-  to induce 
or augment the immune response against transformed cells- 
are the opposite of those for autoimmune diseases. Explora- 
tion of the immune repertoire against human cancer points 
to restricted differentiation antigens as a starting point for 
understanding the antigens recognized on cancer cells. 
Address correspondence  to Dr. Alan N. Houghton, Clinical  Immunology Service, Memorial  Sloan-Kettering 
Cancer Center, 1275 York Avenue, New York, NY 10021. 
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